Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Dose Thrombolytic Treatment in Intermediate High-risk Acute Pulmonary Embolism
NCT04430569Phase 3Active, not recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2021
- Primary completion
- Apr 2026
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 14
01
Overview
A Phase 3 trial of tissue-plasminogen activator in pulmonary embolism (PE), sponsored by Assistance publique - Hôpitaux de Paris. Started Aug 2021; status: active, not recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT04430569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04430569.